Orphazyme : Results of the pivotal II/III phase in NPC in the next few weeks
>NPCÂ around 10% of our valuation: results of phase II/III in Q3 2018e - At its capital markets day end-May, Orphazyme confirmed that the phase II/III results evaluating arimoclomol in the Niemann Pick Type C (NPC) diseases would be communicated Q3 2018 (the final visit to the last patient has taken place). The results will therefore be published over the next few weeks. There are two scenarios in the event of positive results, i.e. 1/ the results are positive and stat...Orphazyme A/S Formerly known as Orphazyme ApS. Orphazyme A/S, formerly Orphazyme ApS, is a Denmark-based company active within the biopharmaceutical industry. It develops new therapies for the treatment of a family of genetic disorders. The Company's main focus is on preclinical development of medicines for the treatment of lysosomal storage diseases (LSDs), a group of approximately 50 genetic disorders that result from deficiencies of lysosomal enzymes or other lysosomal components, and protein aggregation diseases. The Company's candidate, arimoclomol, stimulates the production of the cells' protein rescue system, the heat shock proteins, which helps the misfolded proteins to either get back to their functional shape or, if this cannot be achieved, remove them from the cells by means of the cells' recycling system, the lysosomes, so they no longer form toxic aggregates. The Company collaborates with academic institutions in Europe and the United States.
Oddo Securities provides securities brokerage and research services. The company offers equity, economic, and derivatives research and credit analysis services. It focuses on insurance, automotive, building materials, pharmaceuticals, telecommunications, information technology, and agri-food industries.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.